REDUCTION OF CENTRAL-NERVOUS-SYSTEM REPERFUSION INJURY IN RABBITS USING DOXYCYCLINE TREATMENT

被引:44
作者
CLARK, WM
CALCAGNO, FA
GABLER, WL
SMITH, JR
COULL, BM
机构
[1] OREGON HLTH SCI UNIV,SCH DENT,DEPT BIOL STRUCT & FUNCT,PORTLAND,OR 97201
[2] OREGON HLTH SCI UNIV,SCH DENT,DEPT ORAL MOLEC BIOL,PORTLAND,OR 97201
[3] VET ADM MED CTR,DEPT NEUROL,PORTLAND,OR
关键词
LEUKOCYTES; CEREBRAL ISCHEMIA; REPERFUSION; DOXYCYCLINE;
D O I
10.1161/01.STR.25.7.1411
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose Activated leukocytes appear to potentiate central nervous system reperfusion injury, and agents that block leukocyte adhesion have shown neuroprotective efficacy in experimental models. Doxycycline, a tetracycline antibiotic, inhibits leukocyte function in vitro, presumably through divalent cation binding. We used a model of focal central nervous system reperfusion injury to determine the efficacy of doxycycline treatment in preserving neurological function. Methods Rabbits randomly received 10 mg/kg IV doxycycline 30 minutes before ischemia (pretreatment group) or 45 minutes after ischemia (posttreatment group) or received phosphate-buffered saline vehicle (control group) followed by 10 mg/kg q 8 hours times two. The average length of reversible spinal cord ischemia required to produce paraplegia (P-50) at 18 hours was calculated for each group. Results For the control group (n=13), the P-50 was 22.8+/-2.2 minutes; for the pretreatment group (n=14), 35.5+/-2.4 minutes (P<.01; t=3.8); and for the posttreatment group (n=13), 31.4+/-4.2 minutes (not significant; t=1.6). Doxycycline also attenuated postischemic decreases in in vivo leukocyte counts and inhibited in vitro leukocyte adhesion. Therapeutic doxycycline levels at 24 hours were confirmed in the plasma and spinal cord. Conclusions This significant protective effect suggests that doxycycline, a safe and readily available agent, may play a role in reducing clinical central nervous system reperfusion injury.
引用
收藏
页码:1411 / 1415
页数:5
相关论文
共 33 条
  • [1] INTEGRINS AND OTHER CELL-ADHESION MOLECULES
    ALBELDA, SM
    BUCK, CA
    [J]. FASEB JOURNAL, 1990, 4 (11) : 2868 - 2880
  • [2] AMES A, 1968, AM J PATHOL, V52, P437
  • [3] ARNAOUT MA, 1990, BLOOD, V75, P1037
  • [4] MONOCYTE-LYMPHOCYTE DISCRIMINATION IN A NEW MICROTITRE-BASED ADHESION ASSAY
    BATH, PMW
    BOOTH, RFG
    HASSALL, DG
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1989, 118 (01) : 59 - 65
  • [5] HUMAN NEUTROPHIL ADHERENCE TO LAMININ INVITRO - EVIDENCE FOR A DISTINCT NEUTROPHIL INTEGRIN RECEPTOR FOR LAMININ
    BOHNSACK, JF
    AKIYAMA, SK
    DAMSKY, CH
    KNAPE, WA
    ZIMMERMAN, GA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 171 (04) : 1221 - 1237
  • [6] BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
  • [7] Clark W M, 1992, J Stroke Cerebrovasc Dis, V2, P80, DOI 10.1016/S1052-3057(10)80210-1
  • [8] REDUCTION OF CENTRAL-NERVOUS-SYSTEM ISCHEMIC-INJURY IN RABBITS USING LEUKOCYTE ADHESION ANTIBODY TREATMENT
    CLARK, WM
    MADDEN, KP
    ROTHLEIN, R
    ZIVIN, JA
    [J]. STROKE, 1991, 22 (07) : 877 - 883
  • [9] REDUCTION OF CENTRAL-NERVOUS-SYSTEM ISCHEMIC-INJURY BY MONOCLONAL-ANTIBODY TO INTERCELLULAR-ADHESION MOLECULE
    CLARK, WM
    MADDEN, KP
    ROTHLEIN, R
    ZIVIN, JA
    [J]. JOURNAL OF NEUROSURGERY, 1991, 75 (04) : 623 - 627
  • [10] DELZOPPO G, 1991, STROKE, V22, P276